What led to the stock price crash of Sudeep Pharma today?

Synopsis: The shares of this pharma stock crashed 6% following its Q2 results, which showcased flat-to-falling data in its financials, with revenue up by 9% YoY but PAT down by 4% YoY and more.  Let us see more about the company’s Q2 highlights and reasons why it fell today. 

The shares of this company, which is a manufacturer of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients and serves over 100 countries, had its shares tumble today after its Q2 results. Let us see how the company has performed and why its shares fell.

With a market cap of Rs 7,523 crore, the shares of Sudeep Pharma Ltd fell 6 percent in today’s trading session and reached a low of Rs 644.90 when compared to its previous day’s closing price of Rs 686.30. The stock is trading at a PE of 55.4 compared to its industry PE of 30.7.

Q2 FY26 Result highlights.

The revenue from operations for the company stood at Rs 162.7 crore when compared to Rs 148.8 crore in Q2 FY25, growing by about 9 per cent YoY and up by about 30 per cent from Rs 125 crore in Q1 FY26.

The PAT fell by about 4 per cent YoY when you compare the Q2 FY26 profit at Rs 46.8 crore to Rs 48.7 crore in Q2 FY25 and on a QoQ basis has grown 50 per cent from Rs 31.27 crore in Q1 FY26. 

There has also been a fall in the EBITDA margin, as it stands at 38% in Q2 FY26, whereas it was at 43.4% in Q2 FY25. Similarly, the PAT margin also saw a fall from 32.4% in Q2 FY25 to 27.1% in Q2 FY26. 

Due to this flat-to-falling performance in the financial numbers, the company witnessed a 6% fall in its share price. The market has certain expectations from companies when it comes to results; as Sudeep Pharma could not beat the market’s expectations, it tumbled accordingly. 

About the company and more. 

Sudeep Pharma manufactures ingredient solutions used in the pharmaceutical, nutraceutical, and food industries. With more than three decades of operating experience, the company focuses on maintaining strong quality standards and dependable manufacturing processes. Its work is centred on supporting health and nutrition needs by supplying consistent and reliable ingredients to its customers.

The company has built a deep and trusted relationship with a wide range of global pharmaceutical and nutrition leaders, including Danone, Pfizer, Merck, Aurobindo, Mankind, Alembic, Cadila, Intas, and Micro Labs. It serves over 1,100 customers across more than 100 countries, with 83.17% of revenue coming from repeat business, highlighting strong customer stickiness. Its client base is well diversified, with the largest customer contributing 14.58%, while the top 5 and top 10 customers account for 34.08% and 42.10% of revenue, respectively.

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post What led to the stock price crash of Sudeep Pharma today? appeared first on Trade Brains.